Taxotere Would Be Unaffected By Alimta Approval, Aventis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis expects Taxotere growth to remain unchanged should FDA approve Lilly's thymidylate synthase inhibitor Alimta for the treatment of second line non-small cell lung cancer
You may also be interested in...
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.
Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk
A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.